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Abstract
Background: Previously, we identified the mitotic arrest deficient protein MAD2B (MAD2L2) as a bona fide interactor of the
renal cell carcinoma (RCC)-associated protein PRCC. In addition, we found that fusion of PRCC with the transcription factor
TFE3 in t(X;1)(p11;q21)-positive RCCs results in an impairment of this interaction and, concomitantly, an abrogation of cell
cycle progression. Although MAD2B is thought to inhibit the anaphase promoting complex (APC) by binding to CDC20 and/
or CDH1(FZR1), its exact role in cell cycle control still remains to be established.
Methodology/Principal Findings: Using a yeast two-hybrid interaction trap we identified the small GTPase RAN, a well-
known cell cycle regulator, as a novel MAD2B binding protein. Endogenous interaction was established in mammalian cells
via co-localization and co-immunoprecipitation of the respective proteins. The interaction domain of RAN could be assigned
to a C-terminal moiety of 60 amino acids, whereas MAD2B had to be present in its full-length conformation. The MAD2B-
RAN interaction was found to persist throughout the cell cycle. During mitosis, co-localization at the spindle was observed.
Conclusions/Significance: The small GTPase RAN is a novel MAD2B binding protein. This novel protein-protein interaction
may play a role in (i) the control over the spindle checkpoint during mitosis and (ii) the regulation of nucleocytoplasmic
trafficking during interphase.
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Introduction
The accuracy of cell cycle progression is monitored by several
checkpoints in order to preserve the integrity of the DNA and to
prevent the occurrence of chromosomal aneuploidy. Various
components of one of these checkpoints, the mitotic spindle
checkpoint, have been identified in the budding yeast Saccharomyces
cerevisiae by studying the effects of microtubule destabilizing drugs.
Subsequently, several orthologs and paralogs of the genes
involved, i.e., the BUB and MAD genes, were identified in a
number of species including human [1–6]. The high degree of
sequence relatedness among these genes and its corresponding
proteins suggests that they may exert conserved functional roles in
cell cycle control [7–10]. Previously, we found that human
MAD2B (MAD2L2), a protein initially identified by Cahill et al.
(1999) [11], interacts with the renal cell carcinoma (RCC)-
associated protein PRCC [12]. In addition, we found that this
interaction is impaired in renal cell carcinomas carrying a
t(X;1)(p11;q21) chromosome translocation and a concomitant
PRCCTFE3 gene fusion. MAD2B can bind indirectly to the
anaphase promoting complex APC. The APC, in turn, can be
activated through cell cycle-dependent associations with regulatory
components such as CDC20 or CDH1 (FZR1) [13]. MAD2B is
thought to inhibit APCCDH1 and APCCDC20 by binding to CDH1
and CDC20, respectively [3,4]. The closely related cell cycle
checkpoint protein MAD2 (MAD2L1) exerts a similar inhibitory
effect through binding to CDC20 [14,15]. In order to further
delineate the putative role of MAD2B in cell cycle control, we
performed a protein-protein interaction screen using MAD2B as a
bait. By doing so, we identified the small GTPase RAN, a well-
known cell cycle regulator [16], as a novel and bona fide MAD2B-
interacting protein. Based on our data and those reported by
others, we propose that this newly identified protein-protein
interaction may play a role in (i) the control over the spindle
checkpoint during mitosis and (ii) the regulation of nucleocyto-
plasmic trafficking during interphase.
Materials and Methods
Yeast two-hybrid assays
Yeast two-hybrid assays were performed essentially as described
before using a hybriZAP human testis cDNA library containing
approximately 46106 independent cDNA clones with an average
insert size of ,1 kb [12,17]. Of these, 16106 clones were
amplified once and 16109 of the resulting plaque forming units
were mass-excised according to the manufacturer’s instructions to
generate an interaction cDNA library in pAD-GAL4. The yeast
strain used for the interaction assays was pJ69-4A (a kind gift from
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Philip James). Positive interactions in this yeast strain can be
selected for by adenine and histidine auxotrophy, next to b-
galactosidase activity. The pJ69-4A strain was co-transfected with
bait plasmid pBDT3C, carrying the human MAD2B coding
sequence (AL031731), and the testis cDNA library using the
Yeastmaker transformation kit (Clontech). To select double
transfectants, containing a pBD and a pAD vector, the transfected
yeast cells were plated on synthetic defined (SD) medium lacking
leucine and tryptophan (-LW). All resulting colonies were
recovered from these plates, titrated, and re-plated on SD medium
lacking histidine, adenine, leucine and tryptophane (-HALW) to
reselect yeast clones expressing MAD2B interacting proteins.
Colonies were allowed to grow for at least 5 days at 30uC after
which replicate filters were lifted and tested for b-galactosidase
activity according to the manufacturer’s instructions (LacZ filter
lift assay; Stratagene). The cDNA inserts of positive clones were
isolated by direct PCR on yeast colonies with two pAD-GAL4
specific oligonucleotides, pAD-for (CTGTCACCTGGTTG-
GACGGACCAA) and pGAD-rev (GTGAACTTGCGGGGTT-
TTTCAG). All resulting PCR products were sequenced using the
same oligonucleotides, and the pAD plasmids of these yeast clones
were rescued in DH5a bacteria. Finally, the interacting cDNA
clones were retransfected together with control plasmids as
reported before [17].
Cloning and sequencing procedures
All cloning procedures were essentially as described before
[17,18]. Sequence analyses were performed at the DNA sequence
facility of the Radboud University Nijmegen Medical Centre using
a 3730 DNA Analyzer (Applied Biosystems). DNA and protein
databases were searched using the BLAST or BLAT search
algorithms at the NCBI or UCSC, respectively. Deletion
constructs of human MAD2B were generated using primers
dispersed at intervals of 150 nt throughout the cDNA sequence.
The 59-end of the forward primers were located at amino acid
positions 1, 51, 101 and 151, respectively, according to
NP_006332. The reverse primers were located at positions 211,
161, 111 and 61. The resulting PCR products were cloned into
pGEM-T (Promega), sequence-verified, and subcloned into the
correct pBDT3C and pGADT3C vectors. Full-length human
MAD2B was cloned in pDEST53 (Invitrogen), pECFP (Clontech),
pDEST303 (Invitrogen), pSG8-VSV [12] and pDEST306 (In-
vitrogen), yielding MAD2B-GFP, MAD2B-CFP, HA-MAD2B,
VSV-MAD2B and FLAG-MAD2B fusion proteins, respectively.
Full-length PRCC was cloned in pCMV-dsRed (Clontech),
yielding a dsRed-tagged fusion protein (PRCC-dsRed). The full
length RAN coding sequence was cloned into pDEST15
(Invitrogen) and pEYFP (Clontech), yielding GST-RAN and
RAN-YFP fusion proteins, respectively.
Cell culture
COS-1, U2OS and HEK293 cells were cultured in DMEM
(Invitrogen) supplemented with 10% FCS, penicillin (100 U/ml)
and streptomycin (100 mg/ml) at 37uC and 7,5% CO2. For the
cellular co-localization studies, cells were transiently transfected
using an Amaxa Nucleofector according to the instructions of the
manufacturer (Lonza). For localization of the proteins, cells were
fixed in 3.7% paraformaldehyde/PBS, pH 7.4 for 30 minutes at
room temperature, permeabilized in PBS/0.2% Triton, and
embedded in Vectashield with DAPI (Vector Labs.). Subsequently,
the cells were analyzed by immunofluorescence and/or confocal
laser scanning microscopy as reported before [17]. Cells were
synchronized in M- or S-phase through a 16 h incubation with
250 ng/ml nocodazole or 2.5 mM hydroxyurea, respectively.
Subsequently, the drugs were removed and the cells were
maintained in culture for various time periods as indicated. The
resulting cell cycle distribution of the cells was determined by
Fluorescence Assisted Cell Sorting (FACS) analysis as described
before [18,19] using 106 cells/ml supplemented with 40 mg/ml
Propidium Iodide.
GST pull-down and co-immunoprecipitation assays
GST-RAN was transfected into BL21-DE3 cells (Promega) and
purified as described before [20]. For the GST pull-down assays,
50 ml of GST-RAN was combined with 100 ml of lysates from
U2OS cells expressing HA-MAD2B. In addition, 50 ml glutathi-
one Sepharose 4B slurry (Amersham Biosciences) was used. A
protease inhibitor cocktail (Roche) was added during all wash
steps. Before use, the sepharose beads were washed twice with
TBS (25 mM Tris pH 7.4 and 150 mM NaCl), followed by a 2 h
incubation of the GST-RAN (and GST alone as a control) with
the beads. After this incubation, the GST-coupled beads were
washed with TBSTD buffer (25 mM Tris pH 7.4, 150 mM NaCl,
1.0% Triton X-100 and 2 mM DTT), and incubated overnight at
4uC with lysates of U2OS cells expressing HA-MAD2B (see
above). After five additional washes with lysis buffer (50 mM Tris-
HCl pH 7.5, 150 mM NaCl and 0.5% Triton X-100) and washing
buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 2 mM MgCl2,
2 mM CaCl2, 1% Triton X-100 and 2 mM DTT) the samples
were denatured and loading onto 4–12% NuPAGE polyacryl-
amide gels (Invitrogen). After electrophoreses the gels were blotted
onto nitrocellulose membranes (Protran, Schleicher and Schuell).
The resulting blots were blocked in PBS with 5% non fat dry milk
and incubated with the anti-MAD2B antibody for 1 h at room
temperature and, subsequently, with either a peroxidase conju-
gated secondary antibody (Zymed), or a fluorescent conjugated
secondary antibody (Molecular Probes). Peroxidase signals were
visualized using auto-radiographic exposure to Kodak X-Omat
films, while fluorescent signals were scanned and analyzed with the
Odyssey system and its associated software (Li-Cor). For the
immunoprecipitation assays, cells were washed three times in ice-
cold PBS and scraped from the tissue culture dishes. Total cell
lysates were prepared in 1 ml lysis buffer (PBS, 10% glycerol,
0.1% NP40, protease inhibitors), kept on ice for 10 min, while
vortexed gently at 2 min intervals, and centrifuged for 30 min at
38.500 rpm at 4uC. The supernatants were pre-cleared in 100 ml
of protein A/G PLUS Sepharose (50% slurry in lysis buffer; Santa
Cruz) for 1 h at 4uC and subsequently centrifuged for 3 min at
2500 rpm at 4uC. Immunoprecipitations were performed with
these pre-cleared supernatants by adding 1–5 mg primary
antibody, followed by a 1 h rotation at 4uC. Subsequently, 25 ml
protein A/G PLUS Sepharose was added to the immune
complexes for 1 h at 4uC. The sepharose-bound immune
complexes were collected by centrifugation (3 min; 2500 rpm;
4uC). The resulting pellets were washed five times with lysis buffer
before antigens were released by heating at 95uC for 5 min.
Western blotting was performed as described above.
Antibodies
A polyclonal rabbit anti-MAD2B antibody was used as
described before [12]. Monoclonal mouse anti-RAN (610340;
BD Biosciences), monoclonal mouse anti-H-RAS (sc-29; Santa
Cruz Biotechnology Inc.) and monoclonal mouse anti-FLAG
(F1804; Sigma) antibodies were used according to the instructions
of the manufacturers. The anti-c-tubulin antibody used was kindly
provided by Be´ Wieringa (Nijmegen, The Netherlands).
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Results
Identification of the small GTPase RAN as a MAD2B
binding protein
To search for novel MAD2B interactors, we used a testis cDNA
library for yeast-two-hybrid screening as described before (see
Materials and methods). Transfection of the MAD2B-bait alone in
yeast cells did not yield any growth on histidine-deficient plates, as
expected. Co-transfection of the bait with the human testis cDNA
interaction library resulted in 92 colonies that grew on fully
selective medium. Of these, 69 were selected for further analysis.
Sequencing revealed that two of these yeast colonies contained
pAD plasmids encoding the C-terminal 60 amino acids (aa 157–
216) of the small GTPase RAN. Co-transfection of these pAD-
RAN plasmids with standard control plasmids encoding lamin-B
and p53 turned out to be negative. However, yeast cells co-
transfected with the MAD2B bait and the pAD-RAN plasmids
were able to grow on fully selective medium and turned blue in a
b-galactosidase assay, thereby validating the yeast two-hybrid
interactions observed.
In order to establish whether MAD2B is also capable of
interacting with full-length RAN, we subsequently introduced its
corresponding sequence into the yeast two-hybrid system.
Conversely, in order to identify the region of MAD2B responsible
for the interaction with RAN, several deletion constructs were
generated lacking consecutive stretches of 50 amino acids at either
the C- or N-terminal regions of the coding sequence (Fig. 1). The
resulting MAD2B (deletion) constructs were transfected into yeast
cells together with full-length RAN and all transfectants were
tested for their ability to grow on fully selective medium and for b-
galactosidase activity. Yeast cells, transfected with full-length RAN
and full-length MAD2B (amino acids 1–211) grew well and
showed a strong b-galactosidase activity and, thus, a strong
interaction. Transfection of MAD2B deletion constructs with full-
length RAN, however, resulted in a complete abrogation of yeast
growth and b-galactosidase activity (Fig. 1) indicating that full
length MAD2B is required for the interaction with RAN. Since the
MAD2B protein almost entirely consists of the HORMA domain
[21], and any deletion which affects this domain results in
abrogation of the interaction, it is likely that the whole domain is
required for the interaction between MAD2B and RAN. In
contrast, the C-terminal 60 amino acids of RAN appear to be
sufficient for the interaction with MAD2B.
Endogenous MAD2B and RAN interact physically
To investigate whether the MAD2B protein interacts directly
with RAN, glutathione S-transferase (GST) pull-down analyses
were performed, using GST-RAN fusion proteins produced in E.
Coli. Full-length HA-tagged MAD2B (HA-MAD2B) proteins were
obtained by transfecting U2OS cells, leading to the generation of a
SDS-PAGE protein band of expected size, 28–29 kDa (Fig. 2A;
Input). After performing GST pull-down assays using the GST-
RAN fusion protein and GST alone, we observed that the
MAD2B protein co-precipitated with the GST-RAN fusion
protein (Fig. 2A), but not with the GST protein, thus confirming
a direct interaction between MAD2B and RAN.
In order to assess the MAD2B-RAN interaction in mammalian
cells, we transiently transfected COS1 cells with VSV-MAD2B
and/or RAN-YFP constructs. Subsequently, immunoprecipita-
tions were performed on single and double transfectants, using
anti-MAD2B and anti-RAN antibodies to precipitate the respec-
tive proteins (Fig. 2B,C). The resulting immunoprecipitation
products were analyzed using western blotting in conjunction
with either anti-MAD2B (Fig. 2B) or anti-RAN (Fig. 2C)
antibodies. Total lysates were loaded as controls (Fig. 2B,C;
Input). In single MAD2B and double MAD2B/RAN transfec-
tants, MAD2B was readily detected as a ,28 kDa protein
(including the VSV-tag; Fig. 2B) which was not present in single
RAN transfectants. Conversely, in single RAN and double
MAD2B/RAN transfectants, as well as in untransfected cells,
RAN could readily be detected as a ,21 kDa protein (Fig. 2C),
which corresponds to the size of the endogenous protein. Based on
this latter observation we conclude that the anti-RAN antibody
used does not recognize RAN-YFP protein on western blot.
Subsequently, protein extracts from cells transfected with MAD2B
were subjected to immunoprecipitation with the anti-RAN
antibody. Analysis of these precipitates by western blotting with
the MAD2B antibody revealed co-immunoprecipitation of
Figure 1. Yeast two-hybrid analysis of full length RAN with MAD2B deletion constructs. Schematic representation of the MAD2B full length
protein and deletion constructs (numbers correspond to amino acid positions) used in the assay and the capacity of the respective co-transfected yeast
cells to grow on selective medium (-HALW). The presence of b-galactosidase activity (b-gal) as measured in filter lift assays is indicated by +.
doi:10.1371/journal.pone.0007020.g001
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MAD2B with RAN, but not with a pre-immune control (Fig. 2B).
This physical interaction between exogenous MAD2B and
endogenous RAN was also confirmed vice versa, i.e., after
immunoprecipitation with the anti-MAD2B antibody endogenous
RAN could readily be detected (Fig. 2C). The variations observed
in band intensities are due to variations in the respective
transfection efficiencies. In order to exclude cell-type specific
effects, these immunoprecipitations were replicated in HEK293
cells in the same fashion as outlined above. Again, we observed co-
immunoprecipitation of exogenous MAD2B and endogenous
RAN (data not shown).
Finally, we performed anti-MAD2B immunoprecipitations with
protein extracts from non-transfected HeLa cells. Western blotting
using the anti-RAN antibody, revealed the presence of the
endogenous RAN protein both in the input and the anti-MAD2B
immunoprecipitate, but not in the mock (IgG) immunoprecipitate
(Figure 2D), thus supporting a completely endogenous interaction
between MAD2B and RAN. Taken together, these combined
immunoprecipitation analyses confirm the presence of an in vivo
physical interaction between these two proteins in mammalian cells.
Immunoprecipitation of several (FLAG-tagged) MAD2B dele-
tion fragments that were also used in our yeast two-hybrid screens
failed to pull down RAN (Fig. 2E), indicating that, in full
conformity with the yeast two-hybrid data, also in mammalian
cells full-length MAD2B is required for the interaction with RAN.
In order to assess the specificity of the MAD2B-RAN interaction,
we included RAN family member H-RAS as a negative control.
Again co-immunoprecipitation of MAD2B with RAN was readily
detected, whereas no co-immunoprecipitation of MAD2B with H-
RAS was observed (Fig. 2F), thus confirming that the physical
interaction observed between MAD2B and RAN is specific.
MAD2B and RAN co-localize within mammalian cells
To assess whether the observed interaction between MAD2B and
RAN is operative in mammalian cells, we determined the sub-cellular
localization of both proteins in U2OS cells. To this end, an expression
construct carrying the full coding sequence of GFP-tagged MAD2B
was transiently transfected into U2OS cells, after which the sub-
cellular localizations of MAD2B and (endogenous) RAN were
assayed by fluorescence microscopy. By doing so, we observed a
(near) perfect co-localization of both proteins during interphase
(Figure S1A). In order to substantiate these results, we performed
complete endogenous co-localization assays in U2OS cells in
conjunction with confocal laser scanning microscopy. The results
obtained are in full conformity with the above notion that MAD2B
and RAN co-localize in interphase cells. In addition, we found a
Figure 2. Co-immunoprecipitation of MAD2B and RAN proteins. (A) U2OS cells expressing HA-MAD2B protein were lysed and probed for
interaction with either GST-RAN or GST alone. Specific interaction between MAD2B and RAN was detected by western blot analysis using an anti-
MAD2B antibody. (B, C) COS-1 cells were transiently transfected with MAD2B, RAN or both as indicated on top. Immunoprecipitations were
performed with pre-mouse serum (M IgG), pre-rabbit serum (R IgG), anti-MAD2B and anti-RAN antibodies as indicated. Western blot analyses were
performed with (B) an anti-MAD2B antibody, and (C) an anti-RAN-antibody. The positions of the immunoreactive MAD2B and RAN proteins are
marked on the right. The (co-)immunoprecipitated MAD2B (B) and RAN (C) proteins are marked with arrowheads. The background bands represent
immunoglobulin heavy and light chains, respectively. (D) Immunoprecipitations were carried out with an anti-MAD2B antibody and a control rabbit
antibody (IgG) on HeLa cell lysates as indicated. Western blots analyses were performed with an anti-RAN (upper panel) and an anti-MAD2B (lower
panel) antibody, respectively. (E) COS-1 cells were transiently transfected with FLAG-MAD2B protein and FLAG-tagged deletion constructs of MAD2B
as indicated (see also Fig. 1). Upper panel: immunoprecipitations with an anti-RAN antibody, lower panel: input lysates. The background bands in the
upper panel represent immunoglobulin light chains. Western blot analyses were performed with an anti-FLAG antibody. (F) COS-1 cells were
transiently transfected with MAD2B and immunoprecipitations were performed with anti-RAN and anti-H-RAS antibodies, respectively. A pre-mouse
serum (IgG) was included as a negative control. Western blot analysis was performed with an anti-MAD2B antibody.
doi:10.1371/journal.pone.0007020.g002
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perfect co-localization at the spindle, i.e., c-tubulin, during mitosis
(Fig. 3). In order to further specify this localization at the mitotic
spindle, we were able to exclude that endogenous RAN co-localizes
with histone-2B (Figure S1B), thus indicating that RAN is not
associated with chromatin. Based on these combined results, we
conclude that MAD2B and RAN share similar sub-cellular
localizations in mammalian cells, both during interphase and mitosis.
The MAD2B-RAN interaction persists throughout the cell
cycle
Since MAD2B and RAN have been proposed to regulate
various cell cycle processes [3,4,22], we decided to assess whether
the observed interactions between these two proteins may relate to
different phases of the cell cycle. To this end, COS-1 cells were
transfected with VSV-MAD2B and, subsequently, aliquots of these
Figure 3. Sub-cellular (co-)localization of MAD2B and RAN. Endogenous MAD2B, RAN and c-tubulin (mitotic spindle) are shown in green, red
and white, respectively. DAPI staining (blue) was used to mark nuclei and chromosomes. The overlay of the different signals (Merge) reveals a near
perfect co-localization of the respective proteins at the mitotic spindle (arrows). Images were captured using confocal laser scanning microscopy.
doi:10.1371/journal.pone.0007020.g003
Figure 4. MAD2B and RAN interact throughout the cell cycle. COS-1 cells were transiently transfected with MAD2B, blocked at different
phases in the cell cycle and, subsequently, released from these cell cycle blocks during different time intervals. (1) cells isolated from a confluent
culture, (2) cells isolated 3 h after 1:2 splitting of a confluent culture, (3) cells blocked with nocodazole, (4) cells blocked with nocodazole and released
for 4 h, (5) cells blocked with nocodazole and released for 8 h, (6) cells blocked with hydroxyurea, and (7) cells blocked with hydroxyurea and released
for 6 h. (A) FACS profiles confirming the presence of the cells in the different phases of the cell cycle are shown. (B) Western blot analysis of total
lysates with anti-RAN, anti-MAD2B and anti-c-tubulin antibodies (Input) and after anti-RAN immunoprecipitation of the respective lysates (1–7) using
an anti-MAD2B antibody (IP).
doi:10.1371/journal.pone.0007020.g004
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transfected cells were synchronized by adding either nocodazole
(G2/M phase block) or hydroxyurea (S phase block). Subsequent-
ly, the synchronized cells were released from drug-treatment
during several time intervals as indicated (Fig. 4). To confirm the
efficiency of synchronization, cells were fixed and analyzed by
FACS at all time intervals. After harvesting cells from confluent
cultures, and cultures that were split and allowed to grow for 3 h,
most cells were found to be in the G0/G1 phase of the cell cycle,
as expected (Fig. 4A, panel 1 and 2, respectively; 2N). After
nocodazole treatment, most cells were arrested in the G2/M phase
of the cell cycle, again as expected (Fig. 4A, panel 3; 4N), whereas
subsequent release from this block for 4 and 8 h resulted in
passage of the cells through mitosis and re-entry into the G0/G1
phase of the cell cycle (Fig. 4A; panel 4 and 5, respectively). Also as
expected, treatment of the cells with the DNA replication inhibitor
hydroxyurea provoked a block in the S phase, whereas after a
release of this block for 6 h most of the cells were in the G2/M
phase of the cell cycle (Fig. 4A; panel 6 and 7, respectively).
Simultaneous to these analyses, cell lysates were prepared from
the above described samples (1–7) and assayed for the presence of
MAD2B and RAN proteins using western blotting. As a loading
control anti-c-tubulin was included. The same lysates were also
used for co-immunoprecipitation experiments in order to assess
the putative state of interaction between MAD2B and RAN
during the different phases of the cell cycle. In all lysates tested
endogenous RAN and exogenous MAD2B were found to be
present (Fig. 4B; Input). The levels of RAN and MAD2B protein
showed no overt differences between the (sub)confluent, nocoda-
zole and/or hydroxyurea treated cells (Fig. 4B; Input). Immuno-
precipitations with anti-RAN antibody followed by western
blotting and detection with anti-MAD2B antibody revealed co-
immunoprecipitation during all phases of the cell cycle tested
(Fig. 4B; IP). From these data we conclude that the MAD2B-RAN
interaction observed persists throughout the cell cycle.
MAD2B interacts with either RAN or PRCC
Previously, we found that MAD2B can interact with the renal
cell carcinoma associated protein PRCC [12]. To assess whether
PRCC may act as an integral component of the MAD2B-RAN
complex, U2OS cells were transiently (co-)transfected with
MAD2B-CFP, PRCC-dsRed and/or RAN-YFP expression con-
structs. Subsequently, the transfected cells were assayed for the
sub-cellular localization of the respective proteins. By doing so, we
found that single PRCC transfectants showed a nuclear staining
pattern as reported before [12]. Double MAD2B and PRCC
transfectants showed a nuclear co-localization, again in accor-
dance with our previous observations [12]. Triple MAD2B, PRCC
and RAN transfectants showed a partial co-localization of
MAD2B, RAN and PRCC (Fig. 5). As a control, to again exclude
chromatin association, we tested whether endogenous PRCC co-
localizes with histone-2B. This was not found (Figure S2). Taken
together, we conclude that MAD2B, RAN and PRCC share
similar sub-cellular compartments. The partial co-localization
observed between these three proteins indicates that the
interactions of MAD2B with either RAN and/or PRCC may be
dynamic in nature. To test whether PRCC and RAN can interact
directly, we performed co-immunoprecipitation analyses. By doing
so, no co-immunoprecipitation between PRCC and RAN was
observed, thus excluding a direct interaction between these two
proteins (data not shown).
Discussion
Using a yeast two-hybrid interaction trap we identified the small
GTPase RAN as a novel MAD2B interacting protein. An
endogenous interaction of these proteins was confirmed in
mammalian cells using several in vitro and in vivo assays. Co-
expression of MAD2B and RAN in COS-1 cells revealed a near
perfect co-localization in both during interphase and mitotis.
Using confocal laser scanning microscopy, we found that the
respective endogenous proteins exhibited very similar sub-cellular
co-localization patterns, in particular at the mitotic spindle. A
concomitant physical interaction was found to be present
throughout the different phases of the cell cycle tested.
The interaction domain of RAN could be assigned to its C-
terminal moiety. A previous analysis of the 3-dimensional structure
of RAN has revealed that, when RAN is complexed with importin
b-related proteins, its C-terminal moiety is exposed at the outside
of the molecule [23–25]. Such an exposure may render RAN
accessible for interactions with other proteins such as MAD2B. On
the other hand, full length MAD2B protein appeared to be
required for the interaction with RAN, as observed in both our co-
immunoprecipitation and yeast two-hybrid analyses. This require-
ment may be related to a proper folding of the protein and/or a
proper exposure of its interaction interface(s). Alternatively, the
formation of multimeric MAD2B configurations, a feature that has
been documented extensively for the various protein-protein
interactions exhibited by its closely related homolog MAD2
[26,27], may be essential for the MAD2B-RAN interaction.
There is ample evidence indicating that RAN is at the regulatory
heart of several processes governing the proper execution of mitosis
[28,29]. The mechanisms through which RAN controls these
processes, however, are not yet fully understood. Our current results
suggest that MAD2B, through its interaction with RAN, may also
be involved in these processes. A suggestion for such a role comes
from the observation that ribonucleoprotein complexes, which are
Figure 5. Sub-cellular (co-)localization of MAD2B, RAN and PRCC in U2OS cells. U2OS cells were transiently (co-)transfected with MAD2B-
CFP (green), PRCC-dsRed (red) and/or RAN-YFP (yellow) expression constructs. The overlay of the different signals (Merge) reveals a partial co-
localization of the respective proteins. Images were captured using fluorescence microscopy.
doi:10.1371/journal.pone.0007020.g005
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transported across the nuclear membrane, are required for a correct
mitotic spindle assembly [30]. Next to RAN (this report) and PRCC
[12], trichosanthin (TCS) [31], HCCA2 [32], Elk-1 [33], IpaB [34],
TCF4 [35] and adenovirus death protein (ADP) [36] have been
identified as MAD2B binding proteins. ADP is a membrane
spanning protein which mediates adenovirus-induced cell lysis.
Since efficient nucleocytoplasmic transport of viral RNAs is essential
for cell lysis, and since overexpression of MAD2B results in the
inhibition thereof [36], MAD2B may also be linked to ribonucleo-
protein transport across the nuclear membrane and, thus, mitotic
spindle assembly.
Another indication that suggests a more general RAN-
associated function in cell cycle control comes from the
observation that RAN may exhibit a dual role, depending on
the RAN binding protein RANBP1. The RAN-RANBP1 complex
has been implicated in cell cycle progression and RNA export,
while RAN alone has been implicated in nuclear protein import.
By competing with RANBP1 for binding to RAN [31,36],
MAD2B may affect the export of RNA and, thus, the targeting
of ribonucleoprotein complexes. Such a role would also be
compatible with the here observed interaction between MAD2B
and RAN and the perseverance of this interaction throughout the
different phases of the cell cycle.
Proteolysis and spatial control are two key mechanisms that
regulate critical events during the cell cycle. An important
mediator of these cell cycle-associated processes is the anaphase
promoting complex (APC) [13]. Previously, it was found that the
RAN-dependent complex Rae1/Nup98, which shares both
sequence and structural homologies to several BUB checkpoint
factors, interacts with the CDH1 regulatory component of the
APC. In addition, it was found that elevated levels of Rae1/Nup98
prevent APCCDH1-dependent proteolysis of securin and, thereby,
exit from mitosis. Conversely, dissociation of Rae1/Nup98 from
APCCDH1 was suggested to contribute to mitotic progression [37].
Our results point at a similar RAN-dependent mitotic control
function via its interaction with the CDH1-binding protein
MAD2B [3,4]. The APCCDH1 complex is also crucial for
maintaining cells in the G1 phase of the cell cycle in order to
prevent premature progression into the S phase. Nuclear export of
CDH1 relies on RAN GTPase and results in the inhibition of APC
activity [38]. Since MAD2B can interact with both CDH1 and
RAN, we assume that this protein may also affect nucleocytoplas-
mic transport of CDH1 and, consequently, the activity of the
APCCDH1 complex during the G1 phase of the cell cycle. Thus,
through its association with RAN, MAD2B may be involved in
controlling the transport of CDH1 across the nuclear membrane
and, by doing so, the transition from the G1 to the S phase of the
cell cycle as well.
Since we have found that exogenous co-expression of MAD2B
and PRCC results in translocation of MAD2B from the cytoplasm
to the nucleus where it co-localizes with PRCC, we previously
suggested that MAD2B may travel across the nuclear membrane
when bound to PRCC [12]. This suggestion is in line with our
subsequent observation that MAD2B contains a potential nuclear
localization signal [6]. Alternatively, however, MAD2B may travel
across the nuclear membrane when bound to RAN, a notion that
would be in agreement with our current PRCC co-localization
assays and our suggestion that the respective MAD2B-PRCC and
MAD2B-RAN interactions may be dynamic in nature.
In conclusion, we have identified the small GTPase RAN as a
novel bona fide interactor of the mitotic arrest deficient protein
MAD2B. It has been suggested by others that RAN may be
involved in cellular transformation through interactions with viral
oncogenes [29,39]. Our data suggest that in t(X;1)(p11;q21)-
positive renal cell carcinomas a PRCCTFE3-mediated interfer-
ence with RAN-dependent MAD2B activity may lead to loss of
control over cell cycle progression and, hence, malignant growth.
Supporting Information
Figure S1 Sub-cellular (co-)localization of MAD2B and RAN.
(A) U2OS cells were transiently transfected with MAD2B-GFP
and, subsequently, MAD2B was detected in green. Endogenous
RAN was detected in red and DAPI staining (blue) was used to
mark the position of the nucleus. The overlay of the different
signals (Merge; yellow) reveals a near perfect co-localization of the
respective proteins. (B) Sub-cellular localization of RAN (red)
relative to histone-2B (H2B, green). The overlay of the different
signals (Merge) reveals a lack of co-localization. Images were
captured using fluorescence microscopy.
Found at: doi:10.1371/journal.pone.0007020.s001 (4.44 MB TIF)
Figure S2 Sub-cellular localization of PRCC in U2OS cells.
Sub-cellular localization of PRCC (red) relative to histone-2B
(H2B, green). The overlay of the different signals (Merge) reveals a
lack of co-localization. Images were captured using fluorescence
microscopy.
Found at: doi:10.1371/journal.pone.0007020.s002 (0.61 MB TIF)
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